Quick Answer
Phio Pharmaceuticals Corp. reported Research And Development Expense of $4.62 million for the year ending 2025.
- Phio Pharmaceuticals Corp. showed an increase of +26.8% in Research And Development Expense from 2024 to 2025.
- This data is from Phio Pharmaceuticals Corp.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Phio Pharmaceuticals Corp.'s Research And Development Expense has declined by 30.3%.
- Historical annual values: Fiscal year 2025: $4.62 million | Fiscal year 2024: $3.64 million | Fiscal year 2023: $6.33 million | Fiscal year 2022: $7.01 million | Fiscal year 2021: $8.89 million | Fiscal year 2020: $3.72 million | Fiscal year 2019: $4.30 million | Fiscal year 2018: $4.33 million | Fiscal year 2017: $5.37 million | Fiscal year 2016: $5.42 million | Fiscal year 2015: $6.93 million | Fiscal year 2014: $5.68 million | Fiscal year 2013: $17.65 million | Fiscal year 2012: $10.45 million | Fiscal year 2011: $6.62 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: